TrialFrontiers in immunology2022

FcRn Antagonism Leads to a Decrease of Desmoglein-Specific B Cells: Secondary Analysis of a Phase 2 Study of Efgartigimod in Pemphigus Vulgaris and Pemphigus Foliaceus.

Maud Maho-Vaillant et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.